Ophthalmic Viscoelastic Devices Market 2026: Trends, Leading Ophthalmology Suppliers & How Distributors Can Choose the Right OVD Manufacturer

The global ophthalmic viscoelastic devices market is experiencing sustained growth, driven by an aging population, increasing cataract prevalence, technological advances in ophthalmic surgery, and the expanding adoption of premium intraocular lenses (IOLs). For distributors, hospital procurement teams, and ophthalmology clinics, this evolution presents significant opportunities-but also intensifies the need to identify reliable ophthalmology suppliers capable of delivering consistent product quality, regulatory compliance, and long-term supply stability.

According to the World Health Organization (WHO), cataract remains the leading cause of blindness worldwide, accounting for approximately 94 million people living with vision impairment. Cataract surgery has therefore become one of the most frequently performed surgical procedures globally, with more than 30 million operations conducted annually, and demand continues to rise as populations age.

Every cataract procedure depends on high-quality ophthalmic viscoelastic devices (OVDs) to protect delicate intraocular tissues, maintain anterior chamber stability, and facilitate precise implantation of intraocular lenses. As surgical techniques continue to evolve toward smaller incisions and faster recovery, expectations for OVD performance are also increasing.

This article explores the latest developments shaping the ophthalmic viscoelastic devices market, examines what buyers should look for when selecting ophthalmology suppliers, and explains why experienced manufacturers are becoming valuable strategic partners for distributors worldwide.

The ophthalmic viscoelastic devices market represents one of the fastest-growing segments within ophthalmic surgical consumables. Increasing healthcare expenditure, expanding access to cataract treatment, and the adoption of minimally invasive ophthalmic procedures are all contributing to sustained market demand.

Several factors are driving this growth:

Population aging is the single largest driver of cataract surgery demand.

According to the United Nations World Population Prospects, the global population aged 65 years and older is expected to more than double by 2050. Since cataract incidence increases dramatically with age, ophthalmology departments worldwide are preparing for a substantial rise in surgical volume.

This demographic trend creates continuous demand for reliable ophthalmic viscosurgical devices capable of supporting high-throughput surgical workflows.

Modern phacoemulsification techniques have significantly improved cataract surgery safety and efficiency.

Clinical studies published in the Journal of Cataract & Refractive Surgery (JCRS) report that modern cataract surgery achieves postoperative visual improvement in over 95% of uncomplicated cases, making it one of the most successful surgical interventions in medicine.

However, successful outcomes depend heavily on maintaining the anterior chamber throughout surgery.

A high-quality ophthalmic viscoelastic device plays several essential roles:

Protecting corneal endothelial cells from ultrasound energy

Maintaining surgical space during capsulorhexis

Facilitating intraocular lens implantation

Reducing mechanical trauma to intraocular tissues

Improving overall surgical visibility

Consequently, surgeons increasingly evaluate OVDs not only by price but also by viscosity profile, molecular weight, injectability, transparency, and ease of removal.

The global shift toward premium intraocular lenses-including multifocal, toric, and extended-depth-of-focus (EDOF) lenses-has increased procedural precision requirements.

Compared with conventional cataract surgery, premium IOL implantation demands:

More stable anterior chamber maintenance

Greater surgical precision

Reduced endothelial cell damage

Better visualization during implantation

These requirements have elevated the importance of selecting premium ophthalmic viscosurgical devices with optimized rheological properties.

Numerous peer-reviewed clinical studies have demonstrated that the choice of ophthalmic viscoelastic device can influence intraoperative efficiency and postoperative outcomes.

A systematic review published in the Cochrane Database of Systematic Reviews comparing cohesive and dispersive OVDs found that dispersive OVDs generally provide superior corneal endothelial protection during phacoemulsification, while cohesive OVDs are easier to remove from the anterior chamber. This evidence has led many surgeons to adopt either tailored OVD selection based on surgical complexity or the soft-shell technique, which combines the advantages of both OVD types.

Similarly, studies published in the Journal of Cataract & Refractive Surgery have reported that effective OVD use can help reduce postoperative endothelial cell loss-an important indicator of corneal health following cataract surgery. Although outcomes depend on multiple variables such as surgical technique and cataract density, these findings underscore the importance of choosing products with appropriate viscosity, molecular weight, and tissue-protective characteristics.

For distributors and procurement managers, this means that purchasing decisions should extend beyond cost considerations. Clinical performance, manufacturing consistency, and regulatory compliance have become key differentiators in an increasingly competitive ophthalmic viscoelastic devices market.

Historically, the ophthalmic viscoelastic devices market has been dominated by a limited number of multinational manufacturers. However, several industry trends are reshaping procurement strategies:

Increasing healthcare cost pressures

Diversification of global supply chains

Growing demand for OEM and private-label partnerships

Expansion of ophthalmic surgery in emerging markets

Higher expectations for regulatory compliance and manufacturing transparency

As a result, distributors are increasingly evaluating qualified manufacturers that can deliver performance comparable to established brands while offering greater flexibility, competitive pricing, and responsive technical support.

OVD 17

One example is Singclean® Viscoelastic Solution for Ophthalmic Surgery, which has been developed specifically to support modern cataract and anterior segment procedures. Manufactured using 100% non-animal-source sodium hyaluronate produced through bio-fermentation, the product features a molecular weight of 1.0–2.6 MDa and shear viscosity ranging from 80,000 to 250,000 mPa·s, helping maintain anterior chamber stability while minimizing mechanical stress during phacoemulsification. Additional advantages include terminal sterilization, automated German filling technology, high product transparency, and availability in multiple syringe volumes to accommodate different surgical preferences. To date, the product has achieved cumulative sales exceeding 2.2 million syringes across more than 33 countries and regions, demonstrating its growing international acceptance.

As competition intensifies in the global ophthalmic viscoelastic devices market, procurement decisions are becoming increasingly strategic. Hospitals, ophthalmic distributors, ambulatory surgery centers (ASCs), and private eye clinics are no longer evaluating products solely on price. Instead, they seek long-term partnerships with ophthalmology suppliers that can consistently deliver clinical performance, regulatory compliance, and dependable supply.

For distributors entering new markets or expanding their ophthalmic surgery portfolios, the following evaluation criteria have become essential.

The primary function of an ophthalmic viscoelastic device is to create and maintain a stable surgical environment while protecting delicate intraocular tissues throughout the procedure.

An ideal OVD should provide:

Excellent anterior chamber maintenance

Effective corneal endothelial cell protection

Smooth injector delivery

High optical transparency

Controlled rheological behavior

Easy aspiration at the end of surgery

Peer-reviewed studies have consistently shown that maintaining endothelial cell integrity is one of the most important determinants of successful cataract surgery. Corneal endothelial cells have minimal regenerative capacity; excessive intraoperative damage may result in postoperative corneal edema, delayed visual recovery, and, in severe cases, corneal decompensation.

For this reason, many ophthalmic surgeons prioritize OVDs that combine high molecular weight with optimized viscosity, enabling effective tissue protection without compromising surgical efficiency.

Clinical performance begins long before the operating room.

Reliable ophthalmology suppliers invest heavily in quality management systems, cleanroom manufacturing, raw material traceability, and process validation to ensure product consistency across every production batch.

Distributors should evaluate whether a manufacturer offers:

CE certification

ISO 13485-certified quality management systems

Comprehensive technical documentation

Sterility validation

Biocompatibility testing

Batch traceability

Regulatory support for local product registration

These capabilities reduce regulatory risks while simplifying market access in different countries.

As an established ophthalmic device manufacturer, Singclean operates under internationally recognized quality management standards and has accumulated extensive export experience across Europe, Asia, the Middle East, and Latin America. Its ophthalmic viscoelastic solution is manufactured using 100% non-animal-derived sodium hyaluronate produced through bacterial fermentation, helping eliminate concerns associated with animal-derived raw materials while ensuring excellent purity and consistency.

Since the COVID-19 pandemic, supply chain resilience has become a critical procurement factor.

Hospitals and distributors increasingly prefer manufacturers capable of:

Stable large-scale production

Long-term supply agreements

OEM and private-label manufacturing

Flexible packaging options

Fast international logistics support

Choosing an experienced ophthalmology supplier helps reduce inventory risks while ensuring uninterrupted product availability for high-volume cataract surgery centers.

For distributors, manufacturing capacity is no longer simply a production metric-it is a competitive advantage.

Although many OVD products appear similar on paper, their clinical performance often differs significantly due to variations in sodium hyaluronate quality, molecular weight, viscosity, purification processes, and manufacturing technologies.

Professional buyers should therefore evaluate manufacturers based on technical specifications rather than marketing claims alone.

One of the most important technical indicators is molecular weight.

Higher molecular weight sodium hyaluronate generally provides:

Better space maintenance

Higher viscoelasticity

Improved mechanical cushioning

Greater resistance to deformation during surgical manipulation

According to the Singclean product specifications, the ophthalmic viscoelastic solution features a molecular weight ranging from 1.0 to 2.6 million Daltons, allowing the material to maintain excellent chamber stability while remaining sufficiently manageable during aspiration.

Viscosity is another key indicator influencing surgeon experience.

An OVD should remain sufficiently viscous while static to maintain the anterior chamber, yet demonstrate shear-thinning behavior during injection to facilitate smooth delivery through narrow-gauge cannulas.

Singclean's ophthalmic viscoelastic solution offers:

Performance Parameter	Singclean® OVD
Sodium Hyaluronate	100% Non-animal Source
Concentration	15 mg/mL
Molecular Weight	1.0–2.6 MDa
Shear Viscosity	80,000–250,000 mPa·s
Osmolality	270–350 mOsm/kg
pH	6.8–7.5
Sterilization	Terminal Sterilization

These rheological properties contribute to smooth instrument manipulation while helping maintain anterior chamber depth throughout phacoemulsification.

An often-overlooked factor when selecting an ophthalmic viscoelastic device is removal efficiency.

Residual viscoelastic material left within the anterior chamber may contribute to transient postoperative intraocular pressure (IOP) elevation, particularly in patients with glaucoma or compromised aqueous outflow.

Research has shown that cohesive OVDs are generally easier to aspirate completely than highly dispersive formulations, allowing surgeons to shorten irrigation and aspiration time in routine cataract surgery.

Singclean's optimized rheological profile enables the material to maintain intraoperative stability while remaining relatively easy to remove at the conclusion of surgery, helping improve surgical workflow efficiency.

The ophthalmic industry is witnessing a gradual shift away from reliance on only a handful of multinational brands.

Instead, distributors are increasingly partnering with manufacturers capable of delivering:

Comparable clinical performance

Competitive pricing

Flexible OEM/ODM cooperation

Faster regulatory support

Reliable manufacturing capacity

Stable international logistics

This transition is particularly evident in emerging markets across Southeast Asia, the Middle East, Latin America, and Eastern Europe, where healthcare providers seek cost-effective solutions without compromising surgical quality.

For these markets, selecting the right ophthalmology supplier is not merely about sourcing products-it is about building a long-term partnership that supports sustainable business growth.

For distributors seeking a reliable partner in the expanding ophthalmic viscoelastic devices market, Singclean combines more than product performance with comprehensive manufacturing capabilities.

Key advantages include:

100% bio-fermentation, non-animal-derived sodium hyaluronate for enhanced purity and safety.

High molecular weight (1.0–2.6 MDa) and shear viscosity of 80,000–250,000 mPa·s, supporting stable anterior chamber maintenance during cataract surgery.

Terminal sterilization, automated German filling equipment, and high-cleanliness manufacturing to ensure consistent product quality.

More than 2.2 million syringes sold across 33+ countries and regions, demonstrating proven international market acceptance.

Availability of multiple syringe sizes (0.5 mL, 0.75 mL, 1.0 mL, and 2.0 mL) to accommodate different surgical techniques and clinical preferences.

For distributors and ophthalmic procurement teams, these strengths translate into reliable product performance, scalable supply capacity, and the flexibility needed to support both branded distribution and OEM/private-label partnerships.

More About Us

The ophthalmic viscoelastic devices market is expected to maintain steady growth over the next decade as demographic shifts, technological innovation, and healthcare investment continue to reshape ophthalmic surgery worldwide. For distributors and procurement professionals, understanding these trends is essential for making long-term sourcing decisions.

Population aging remains the strongest long-term growth driver for ophthalmic surgery.

According to the World Health Organization (WHO), the number of people living with vision impairment caused by cataracts continues to increase globally, particularly in low- and middle-income countries where access to surgical treatment is expanding.

At the same time, the United Nations projects that by 2050, one in every six people worldwide will be over the age of 65, significantly increasing the demand for cataract procedures.

For ophthalmology suppliers, this means sustained demand for reliable ophthalmic viscosurgical devices capable of supporting high surgical volumes while maintaining consistent product quality.

The evolution of cataract surgery extends well beyond restoring vision.

Today's patients increasingly expect:

Spectacle independence

Faster visual recovery

Better contrast sensitivity

Improved quality of life

As a result, premium intraocular lenses (IOLs), femtosecond laser-assisted cataract surgery (FLACS), and advanced microsurgical techniques are becoming more widely adopted.

These procedures place greater demands on OVD performance, particularly in terms of:

Chamber stability

Optical clarity

Tissue protection

Controlled injection

Efficient removal

Manufacturers that invest in advanced sodium hyaluronate purification technologies and optimized rheological performance will be well positioned to support the next generation of ophthalmic surgery.

Healthcare providers have become increasingly aware of the importance of supply chain resilience.

Rather than relying on a single source, many distributors now seek manufacturing partners that can provide:

Stable production capacity

International regulatory support

OEM/Private Label capability

Competitive pricing

Long-term technical collaboration

This trend creates new opportunities for experienced ophthalmology suppliers with proven export experience and scalable manufacturing infrastructure.

The global ophthalmic viscoelastic devices market is entering a period of sustained expansion, driven by demographic changes, technological advancements, and rising expectations for cataract surgery outcomes. As the demand for high-quality ophthalmic surgical consumables grows, selecting the right ophthalmology supplier has become a strategic decision rather than a simple procurement exercise.

For distributors, hospitals, and ophthalmic clinics, partnering with a manufacturer that combines clinically optimized products, robust quality systems, international regulatory experience, and reliable manufacturing capacity can provide a significant competitive advantage.

With advanced sodium hyaluronate technology, proven international market acceptance, and flexible OEM capabilities, Singclean is well positioned to support healthcare partners seeking dependable ophthalmic viscoelastic solutions for today's evolving surgical landscape.